Related references
Note: Only part of the references are listed.Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial
Chizuru Sakai et al.
ONCOLOGIST (2021)
Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis
Kenjiro Aogi et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2021)
Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study
Hirotoshi Iihara et al.
GYNECOLOGIC ONCOLOGY (2020)
Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial
Jun Cao et al.
INVESTIGATIONAL NEW DRUGS (2020)
Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Hironobu Hashimoto et al.
LANCET ONCOLOGY (2020)
Antiemetics: ASCO Guideline Update
Paul J. Hesketh et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting
Kazuki Tanaka et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy
Takako Yanai et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2018)
Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy
Hirotoshi Iihara et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2016)
Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin
Hideaki Yahata et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2016)
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
F. Roila et al.
ANNALS OF ONCOLOGY (2016)
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Rudolph M. Navari et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Efficacy of triple antiemetic therapy (palonosetron, dexamethasone, aprepitant) for chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based, moderately emetogenic chemotherapy
Toshimichi Miya et al.
SPRINGERPLUS (2016)
Olanzapine versus fosaprepitant for the prevention of concurrent chemotherapy radiotherapy-induced nausea and vomiting
Rudolph M. Navari et al.
JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY (2016)
Effectiveness of Olanzapine Combined with Ondansetron in Prevention of Chemotherapy-Induced Nausea and Vomiting of Non-small Cell Lung Cancer
Xin Wang et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2015)
Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer
Hideki Kusagaya et al.
LUNG CANCER (2015)
Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy
Takeshi Kitazaki et al.
SUPPORTIVE CARE IN CANCER (2015)
Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy
Yasuhiro Ito et al.
LUNG CANCER (2014)
Preference weights for chemotherapy side effects from the perspective of women with breast cancer
I. Kuchuk et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy
M. Tanioka et al.
BRITISH JOURNAL OF CANCER (2013)
Risk factors of chemotherapy-induced nausea and vomiting: Index for personalized antiemetic prophylaxis
Ikuo Sekine et al.
CANCER SCIENCE (2013)
Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study
Doranne L. Hilarius et al.
SUPPORTIVE CARE IN CANCER (2012)
Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life
P. Fernandez-Ortega et al.
SUPPORTIVE CARE IN CANCER (2012)
Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies
Peter C. Austin
PHARMACEUTICAL STATISTICS (2011)
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy
David G. Warr et al.
SUPPORTIVE CARE IN CANCER (2011)
Efficacy of mirtazapine in preventing intrathecal morphine-induced nausea and vomiting after orthopaedic surgery
F. -L. Chang et al.
ANAESTHESIA (2010)
Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy
Paul J. Hesketh et al.
SUPPORTIVE CARE IN CANCER (2010)
Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting
Lijun Tan et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2009)
Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer
CC Sun et al.
SUPPORTIVE CARE IN CANCER (2005)
Share Paper
